- Dynavax press release ( NASDAQ: DVAX ): Q3 GAAP EPS of $0.43 beats by $0.10 .
- Revenue of $167.74M (+54.9% Y/Y) beats by $8.33M .
- HEPLISAV-B® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021
- CpG 1018® adjuvant net product revenue of $126.3 million, up 50% from $84.3 million for Q3 2021
- Reiterates guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million
- On track for a second consecutive year of profitability.
- 2022 Outlook: Full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million, with an associated gross margin anticipated to be approximately 60%
- Research and development expenses to be between approximately $50-$60 million
- Selling, general and administrative expenses to be between approximately $130-$140 million
For further details see:
Dynavax GAAP EPS of $0.43 beats by $0.10, revenue of $167.74M beats by $8.33M